Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that long-term administration of tamsulosin hydrochloride 0.2 mg is effective, safe, and well-tolerated for improving symptoms and quality of life in patients with LUTS of BPH.

This study observed that women with PCOS had significant differences in body composition and some physiological markers compared to healthy women, which may have implications for pregnancy outcomes and long-term health risks.

This study found that dutasteride effectively improves symptoms of benign prostatic hyperplasia, showing benefits in urinary flow and quality of life, with only modestly elevated sexual side effects compared to placebo.

This review summarizes a meta-analysis suggesting that finasteride is most effective for improving symptoms and urinary flow in men with large prostates experiencing benign prostatic hyperplasia.

This study demonstrated that 12 months of 5 mg daily finasteride treatment reduced prostate volume, dihydrotestosterone, and prostate-specific antigen levels, while improving urinary flow rates and symptom scores in benign prostatic hyperplasia patients.

This study found that after 12 months of treatment with 5 mg of finasteride, patients with benign prostatic hyperplasia showed reduced prostate volume, DHT and PSA levels, and improved urinary flow rates and symptoms.

This study reported that Saw Palmetto, at a physiological dose, partially inhibits 5-alpha-reductase and, when combined with Lycopene, L-Arginine, and Astaxanthin, demonstrates a synergistic effect in restoring hormonal balance, reducing inflammation, and improving hair density, urinary flow, and oxidative biomarkers in related male health conditions.

Researchers created a simple tool to predict bladder blockage from prostate enlargement using urine flow rate and prostate volume.

Saw palmetto helps with nighttime urination and urine flow, similar to finasteride.

This chapter reviews the uses and evidence for saw palmetto in treating lower urinary tract symptoms in men with benign prostate hyperplasia, but finds no strong support for its effect on hair loss.

This study concluded that finasteride may safely reduce prostate size and improve urinary symptoms for at least six years in men with benign prostatic hyperplasia, though further improvements beyond six months are unlikely.

This report discusses Titanflow as a potential improvement in male urinary health by focusing on the detrusor muscle rather than prostate size, suggesting it may offer relief where other supplements have limited effectiveness.

This analysis concluded that finasteride effectively reduces prostate size and urinary symptoms in benign prostatic hyperplasia, offering a favorable safety profile and versatility as a treatment option.

This review discusses the effectiveness and tolerability of alpha1-adrenoceptor antagonists for managing lower urinary tract symptoms in benign prostatic hyperplasia, reporting no new clinical results.

In this study, 5 mg of finasteride per day significantly improved urinary symptoms and reduced prostate volume in men with benign prostatic hyperplasia, but increased the risk of sexual dysfunction.

This study concluded that finasteride is a viable first-line treatment for moderate uncomplicated benign prostatic hyperplasia, particularly in patients with larger prostates, by significantly reducing acute urinary retention and the need for surgery.

This study found that combination therapy with alpha-adrenergic blockers and 5α-reductase inhibitors significantly improved urinary symptoms, reduced prostate volume, and decreased the risk of acute urinary retention and postoperative surgery in patients with benign prostatic hyperplasia compared to monotherapy.

Chewing betel nut may increase the risk of type 2 diabetes, and saw palmetto can improve urinary symptoms in BPH with fewer side effects but may cause bleeding and allergic reactions.

In this study, Leonuri Herba alkaloids significantly reduced prostate hyperplasia indicators and improved urinary parameters in hormone-induced model rats.

This study explores the clinical significance of the intravesical prostatic protrusion/prostate volume ratio in diagnosing bladder outlet obstruction but reports no new results.

Finasteride treats enlarged prostate, shrinks it, improves urination, but may cause sexual dysfunction and isn't for women or children.

Finasteride effectively treats enlarged prostate and male baldness, improves symptoms of hirsutism in women, but doesn't work for acne, and may delay prostate cancer progression with few side effects.

This article reviews the use of finasteride for treating benign prostatic hyperplasia and its chemopreventive potential for prostate cancer, but it calls for further discussion on its preventive use in high-risk groups.

This study reported that cognitive biopsy diagnosed prostate cancer in 44% of patients with at least one previous negative biopsy, with higher detection rates in lesions classified as PI-RADS 4 and 5.

This review discusses 5-alpha reductase inhibitors, highlighting their long-term efficacy and tolerability in treating benign prostate hyperplasia, while also noting sexual dysfunction as a common adverse effect.

This article reviews the use of 5alpha-reductase inhibitors for managing benign prostatic hyperplasia and reports no new clinical results.

This review summarizes existing studies on 5-alpha reductase inhibitors, noting their effectiveness in reducing prostate volume and cancer risk but highlighting an increased risk of higher grade prostate cancer.

This study found that 5α-reductase inhibitors significantly increase the risk of erectile dysfunction and hypoactive sexual desire in men with benign prostatic hyperplasia, compared to placebo.

This review discusses the use of 5α-reductase inhibitors in treating benign prostatic hyperplasia, highlighting their long-term effectiveness and benefits when combined with α1-adrenergic antagonists; it reports no new clinical results.

This article reviews the potential of combining antiandrogenic and antiestrogenic treatments for BPH, highlighting aromatase inhibitors, but presents no new clinical results; further research is needed.